1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile

Betz M, Huxley P, Davies SJ, Mushtaq Y, Pieper M, Tschesche H, Bode W, GomisRuth FX (1997)
EUROPEAN JOURNAL OF BIOCHEMISTRY 247(1): 356-363.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
DOI
Autor*in
Betz, M; Huxley, P; Davies, SJ; Mushtaq, Y; Pieper, M; Tschesche, HaraldUniBi; Bode, W; GomisRuth, FX
Einrichtung
Fakultät für Chemie > Biochemie I
Abstract / Bemerkung
Matrix metalloproteinases (MMP) are zinc endopeptidases involved in tissue remodelling. They have been implicated in a series of pathologies, including cancer, arthritis, joint destruction and Alzheimer's disease. Human neutrophil collagenase represents one of the three interstitial collagenases that cleave triple-helical collagen of type I, II and III. Its catalytic domain (residues Phe79-Gly242) has been heterologously expressed in Escherichia coli and crystallized as a non-covalent complex with the hydroxamate inhibitor BB-1909, which has distinct selectivity against different MMP, in a crystal form. The crystal structure, refined to 0.18-nm resolution, shows that BB-1909 is a right-hand-side inhibitor that binds to the S-1'-S-3' subsites and coordinates to the catalytic Zn2+ in a bidentate manner via the hydroxyl and carbonyl oxygen atoms of the hydroxamate group in a similar manner to batimastat. The collagenase/BB-1909 complex is described in detail and compared with the collagenase/batimastat complex. These studies provide information on MMP specificity and thus may assist the development of more-selective MMP inhibitors.
Stichworte
X-ray crystal structure; protein inhibitor; complex; drug design; matrix metalloprotease
Erscheinungsjahr
1997
Zeitschriftentitel
EUROPEAN JOURNAL OF BIOCHEMISTRY
Band
247
Ausgabe
1
Seite(n)
356-363
ISSN
0014-2956
eISSN
1432-1033
Page URI
https://pub.uni-bielefeld.de/record/1627908

Zitieren

Betz M, Huxley P, Davies SJ, et al. 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY. 1997;247(1):356-363.
Betz, M., Huxley, P., Davies, S. J., Mushtaq, Y., Pieper, M., Tschesche, H., Bode, W., et al. (1997). 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY, 247(1), 356-363. https://doi.org/10.1111/j.1432-1033.1997.00356.x
Betz, M, Huxley, P, Davies, SJ, Mushtaq, Y, Pieper, M, Tschesche, Harald, Bode, W, and GomisRuth, FX. 1997. “1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile”. EUROPEAN JOURNAL OF BIOCHEMISTRY 247 (1): 356-363.
Betz, M., Huxley, P., Davies, S. J., Mushtaq, Y., Pieper, M., Tschesche, H., Bode, W., and GomisRuth, F. X. (1997). 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY 247, 356-363.
Betz, M., et al., 1997. 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY, 247(1), p 356-363.
M. Betz, et al., “1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile”, EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 247, 1997, pp. 356-363.
Betz, M., Huxley, P., Davies, S.J., Mushtaq, Y., Pieper, M., Tschesche, H., Bode, W., GomisRuth, F.X.: 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile. EUROPEAN JOURNAL OF BIOCHEMISTRY. 247, 356-363 (1997).
Betz, M, Huxley, P, Davies, SJ, Mushtaq, Y, Pieper, M, Tschesche, Harald, Bode, W, and GomisRuth, FX. “1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile”. EUROPEAN JOURNAL OF BIOCHEMISTRY 247.1 (1997): 356-363.

31 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS, Lin CW, Su SC, Yang SF., Expert Opin Drug Metab Toxicol 12(2), 2016
PMID: 26852787
Intricate Functions of Matrix Metalloproteinases in Physiological and Pathological Conditions.
Mittal R, Patel AP, Debs LH, Nguyen D, Patel K, Grati M, Mittal J, Yan D, Chapagain P, Liu XZ., J Cell Physiol 231(12), 2016
PMID: 27187048
Targeting angiogenesis for treatment of human cancer.
Somani RR, Bhanushali UV., Indian J Pharm Sci 75(1), 2013
PMID: 23901154
Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.
Chaudhary AK, Pandya S, Ghosh K, Nadkarni A., Mutat Res 753(1), 2013
PMID: 23370482
Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2).
Higashi S, Hirose T, Takeuchi T, Miyazaki K., J Biol Chem 288(13), 2013
PMID: 23395821
A possibility of a protein-bound water molecule as the ionizable group responsible for pKe at the alkaline side in human matrix metalloproteinase 7 activity.
Morishima A, Yasukawa K, Inouye K., J Biochem 151(5), 2012
PMID: 22368250
Computational insights into the selectivity mechanism of APP-IP over matrix metalloproteinases.
Geng L, Gao J, Cui W, Tang Y, Ji M, Chen B., J Comput Aided Mol Des 26(12), 2012
PMID: 23224743
The structure of the catalytic domain of Tannerella forsythia karilysin reveals it is a bacterial xenologue of animal matrix metalloproteinases.
Cerdà-Costa N, Guevara T, Karim AY, Ksiazek M, Nguyen KA, Arolas JL, Potempa J, Gomis-Rüth FX., Mol Microbiol 79(1), 2011
PMID: 21166898
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
Gialeli C, Theocharis AD, Karamanos NK., FEBS J 278(1), 2011
PMID: 21087457
Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor.
Hashimoto H, Takeuchi T, Komatsu K, Miyazaki K, Sato M, Higashi S., J Biol Chem 286(38), 2011
PMID: 21813640
Targeting the tumor microenvironment by immunotherapy: part 2.
Leibovici J, Itzhaki O, Huszar M, Sinai J., Immunotherapy 3(11), 2011
PMID: 22053888
Matrix metalloproteinases in the pathophysiology and progression of gynecological malignancies: could their inhibition be an effective therapeutic approach?
Memtsas V, Zarros A, Theocharis S., Expert Opin Ther Targets 13(9), 2009
PMID: 19604124
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.
Roy R, Yang J, Moses MA., J Clin Oncol 27(31), 2009
PMID: 19738110
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
Moroy G, Denhez C, El Mourabit H, Toribio A, Dassonville A, Decarme M, Renault JH, Mirand C, Bellon G, Sapi J, Alix AJ, Hornebeck W, Bourguet E., Bioorg Med Chem 15(14), 2007
PMID: 17512742
Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma.
Lyons AJ, Jones J., Int J Oral Maxillofac Surg 36(8), 2007
PMID: 17643963
Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, Matziari M, Yiotakis A, Dive V., Biochimie 87(3-4), 2005
PMID: 15781327
Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA., Eur J Surg Oncol 31(9), 2005
PMID: 15993560
Matrix metalloproteinase inhibitors.
Ramnath N, Creaven PJ., Curr Oncol Rep 6(2), 2004
PMID: 14751086
Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12.
Morales R, Perrier S, Florent JM, Beltra J, Dufour S, De Mendez I, Manceau P, Tertre A, Moreau F, Compere D, Dublanchet AC, O'Gara M., J Mol Biol 341(4), 2004
PMID: 15289103
Aromatic hydroxamic acids and hydrazides as inhibitors of the peroxidase activity of prostaglandin H2 synthase-2.
Ouellet M, Aitken SM, English AM, Percival MD., Arch Biochem Biophys 431(1), 2004
PMID: 15464732
Identification of a region of beta-amyloid precursor protein essential for its gelatinase A inhibitory activity.
Higashi S, Miyazaki K., J Biol Chem 278(16), 2003
PMID: 12586836
Structural aspects of the metzincin clan of metalloendopeptidases.
Gomis-Rüth FX., Mol Biotechnol 24(2), 2003
PMID: 12746556
Computational study of the catalytic domain of human neutrophil collagenase. specific role of the S3 and S'3 subsites in the interaction with a phosphonate inhibitor.
Aschi M, Roccatano D, Di Nola A, Gallina C, Gavuzzo E, Pochetti G, Pieper M, Tschesche H, Mazza F., J Comput Aided Mol Des 16(3), 2002
PMID: 12363219
Development of matrix metalloproteinase inhibitors in cancer therapy.
Purcell WT, Rudek MA, Hidalgo M., Hematol Oncol Clin North Am 16(5), 2002
PMID: 12512389
Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.
Matter H, Schudok M, Schwab W, Thorwart W, Barbier D, Billen G, Haase B, Neises B, Weithmann K, Wollmann T., Bioorg Med Chem 10(11), 2002
PMID: 12213468
The 1.8-A crystal structure of a matrix metalloproteinase 8-barbiturate inhibitor complex reveals a previously unobserved mechanism for collagenase substrate recognition.
Brandstetter H, Grams F, Glitz D, Lang A, Huber R, Bode W, Krell HW, Engh RA., J Biol Chem 276(20), 2001
PMID: 11278347
Development of matrix metalloproteinase inhibitors in cancer therapy.
Hidalgo M, Eckhardt SG., J Natl Cancer Inst 93(3), 2001
PMID: 11158186
Structural differences of matrix metalloproteinases. Homology modeling and energy minimization of enzyme-substrate complexes.
Terp GE, Christensen IT, Jørgensen FS., J Biomol Struct Dyn 17(6), 2000
PMID: 10949161
High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
Moy FJ, Chanda PK, Chen JM, Cosmi S, Edris W, Levin JI, Powers R., J Mol Biol 302(3), 2000
PMID: 10986126
Design and synthesis of acidic dipeptide hydroxamate inhibitors of procollagen C-proteinase.
Ovens A, Joule JA, Kadler KE., J Pept Sci 6(9), 2000
PMID: 11016886
Matrix metalloproteases: variations on a theme.
Borkakoti N., Prog Biophys Mol Biol 70(1), 1998
PMID: 9785958

41 References

Daten bereitgestellt von Europe PubMed Central.

Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme.
Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PM, Cameron PM, Esser CK, Hagmann WK, Hermes JD., Protein Sci. 4(10), 1995
PMID: 8535233
Matrix metalloproteinases: a review.
Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA., Crit. Rev. Oral Biol. Med. 4(2), 1993
PMID: 8435466
Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'.
Bode W, Gomis-Ruth FX, Stockler W., FEBS Lett. 331(1-2), 1993
PMID: 8405391
The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity.
Bode W, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H., EMBO J. 13(6), 1994
PMID: 8137810
Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor.
Borkakoti N, Winkler FK, Williams DH, D'Arcy A, Broadhurst MJ, Brown PA, Johnson WH, Murray EJ., Nat. Struct. Biol. 1(2), 1994
PMID: 7656013
Matrilysin-inhibitor complexes: common themes among metalloproteases.
Browner MF, Smith WW, Castelhano AL., Biochemistry 34(20), 1995
PMID: 7756291

AUTHOR UNKNOWN, 0
The CCP4 suite: programs for protein crystallography.
Collaborative Computational Project, Number 4., Acta Crystallogr. D Biol. Crystallogr. 50(Pt 5), 1994
PMID: 15299374
X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily.
Dhanaraj V, Ye QZ, Johnson LL, Hupe DJ, Ortwine DF, Dunbar JB Jr, Rubin JR, Pavlovsky A, Humblet C, Blundell TL., Structure 4(4), 1996
PMID: 8740360

AUTHOR UNKNOWN, 0
Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas.
Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, Lopez-Otin C., J. Biol. Chem. 269(24), 1994
PMID: 8207000
The NMR structure of the inhibited catalytic domain of human stromelysin-1.
Gooley PR, O'Connell JF, Marcy AI, Cuca GC, Salowe SP, Bush BL, Hermes JD, Esser CK, Hagmann WK, Springer JP., Nat. Struct. Biol. 1(2), 1994
PMID: 7656014
Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor.
Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H, Bode W., Biochemistry 34(43), 1995
PMID: 7577999
X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
Grams F, Reinemer P, Powers JC, Kleine T, Pieper M, Tschesche H, Huber R, Bode W., Eur. J. Biochem. 228(3), 1995
PMID: 7737183
Structure of astacin with a transition-state analogue inhibitor.
Grams F, Dive V, Yiotakis A, Yiallouros I, Vassiliou S, Zwilling R, Bode W, Stocker W., Nat. Struct. Biol. 3(8), 1996
PMID: 8756323
MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures.
Kraulis PJ., J Appl Crystallogr 24(5), 1991
PMID: c6694

Kubochi, J. Jpn. Surg. Soc. 91(), 1990
Structure of the zinc endoprotease from Streptomyces caespitosus.
Kurisu G, Kinoshita T, Sugimoto A, Nagara A, Kai Y, Kasai N, Harada S., J. Biochem. 121(2), 1997
PMID: 9089404
PROCHECK: a program to check the stereochemical quality of protein structures.
Laskowski RA, MacArthur MW, Moss DS, Thornton JM., J Appl Crystallogr 26(2), 1993
PMID: c6802

Leslie, 1991
Crystal structures of recombinant 19-kDa human fibroblast collagenase complexed to itself.
Lovejoy B, Hassell AM, Luther MA, Weigl D, Jordan SR., Biochemistry 33(27), 1994
PMID: 8031754
Solvent content of protein crystals.
Matthews BW., J. Mol. Biol. 33(2), 1968
PMID: 5700707

Matthews, Acc. Chem. Res. 21(), 1988
Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours.
Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, Dumont P, Eber M, Abecassis J., Int. J. Cancer 48(4), 1991
PMID: 1646178
Metalloproteinases and cancer invasion and metastasis.
Murphy G, Reynolds JJ, Hembry RM., Int. J. Cancer 44(4), 1989
PMID: 2793248
The origin of matrix metalloproteinases and their familial relationships.
Murphy GJ, Murphy G, Reynolds JJ., FEBS Lett. 289(1), 1991
PMID: 1894005
The matrix metalloproteinases and their inhibitors.
Murphy G, Docherty AJ., Am. J. Respir. Cell Mol. Biol. 7(2), 1992
PMID: 1497900

Murphy, J. Rheumatol. 19(), 1992

AUTHOR UNKNOWN, 0
Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain.
Peress N, Perillo E, Zucker S., J. Neuropathol. Exp. Neurol. 54(1), 1995
PMID: 7815076
Structural implications for the role of the N terminus in the 'superactivation' of collagenases. A crystallographic study.
Reinemer P, Grams F, Huber R, Kleine T, Schnierer S, Piper M, Tschesche H, Bode W., FEBS Lett. 338(2), 1994
PMID: 8307185
The recombinant catalytic domain of human neutrophil collagenase lacks type I collagen substrate specificity.
Schnierer S, Kleine T, Gote T, Hillemann A, Knauper V, Tschesche H., Biochem. Biophys. Res. Commun. 191(2), 1993
PMID: 8460992
1.56 A structure of mature truncated human fibroblast collagenase.
Spurlino JC, Smallwood AM, Carlton DD, Banks TM, Vavra KJ, Johnson JS, Cook ER, Falvo J, Wahl RC, Pulvino TA., Proteins 19(2), 1994
PMID: 8090713
Structure of human neutrophil collagenase reveals large S1' specificity pocket.
Stams T, Spurlino JC, Smith DL, Wahl RC, Ho TF, Qoronfleh MW, Banks TM, Rubin B., Nat. Struct. Biol. 1(2), 1994
PMID: 7656015

Stetler-Stevenson, J. Biol. Chem. 29(), 1989
Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis.
Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr., FASEB J. 7(15), 1993
PMID: 8262328
The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases.
Stocker W, Grams F, Baumann U, Reinemer P, Gomis-Ruth FX, McKay DB, Bode W., Protein Sci. 4(5), 1995
PMID: 7663339
Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family.
Uria JA, Ferrando AA, Velasco G, Freije JM, Lopez-Otin C., Cancer Res. 54(8), 1994
PMID: 8174111
Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis.
Wernicke D, Seyfert C, Hinzmann B, Gromnica-Ihle E., J. Rheumatol. 23(4), 1996
PMID: 8730110
Structure-function relationships in the tissue inhibitors of metalloproteinases.
Willenbrock F, Murphy G., Am. J. Respir. Crit. Care Med. 150(6 Pt 2), 1994
PMID: 7952654
Matrix metalloproteinases and their inhibitors in connective tissue remodeling.
Woessner JF Jr., FASEB J. 5(8), 1991
PMID: 1850705
Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 9249047
PubMed | Europe PMC

Suchen in

Google Scholar